Logo
x

Search

Subscribe Now

cUTI

Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

  • June 26, 2018
Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis

    Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis

    • January 23, 2024
    PharmaShots Weekly Snapshots (January 15 – January 19, 2024)

      PharmaShots Weekly Snapshots (January 15 – January 19, 2024)

      • January 19, 2024
      Insights+: The US FDA New Drug Approvals in December 2023 

        Insights+: The US FDA New Drug Approvals in December 2023 

        • January 17, 2024
        Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermatitis

          Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermat...

          • January 15, 2024
          Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

            Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

            • January 15, 2024
            PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

              PharmaShots Weekly Snapshots (December 18 – December 22, 2023)

              • December 22, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.